About AB&B BIO-TECH-B Company

Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. has a registered capital of RMB 360 million and is dedicated to the research, development, manufacturing, and commercialization of innovative vaccines as well as traditional vaccines employing novel technological approaches. The company's R&D centers in Shanghai and Taizhou, along with its pilot-scale production platform, are concurrently advancing multiple vaccine pipelines covering viral vaccines, bacterial vaccines, conjugate vaccines, subunit vaccines, and mRNA vaccines. Currently, the company's quadrivalent influenza virus subunit vaccine for individuals aged 3 years and older is already on the market. An NDA application for the quadrivalent influenza virus subunit vaccine for infants aged 6–35 months has been accepted for review. The 23-valent pneumococcal polysaccharide vaccine and the lyophilized human rabies vaccine (produced in human diploid cells) have both completed Phase I clinical trials. Several of the company's scientific publications have been featured in the internationally renowned journal Vaccine and have been consistently cited in recent editions of the "Technical Guidelines for Influenza Vaccination in China." The company's No. 1 manufacturing park is equipped with state-of-the-art production facilities, a central laboratory, a warehousing center, and other supporting infrastructure that meet national standards. It has successfully built GMP-compliant production lines for influenza bulk vaccine and finished dosage forms, and has obtained both the Vaccine Production License and the Laboratory Animal Use License. Construction of the No. 2 and No. 3 manufacturing parks is currently underway at full speed. The company has been honored with numerous awards, including "2024 Jiangsu Provincial Specialized, Sophisticated, Distinctive, and Novel SME," "2022 Jiangsu Provincial High-Tech Industrial Development Zone Potential Unicorn Enterprise," "Jiangsu Provincial High-Tech Zone Gazelle Enterprise," and "Top Ten Industrial Transformation and Innovation Investment Projects in Taizhou City." At present, the core team comprises highly qualified professionals from both domestic and international biopharmaceutical manufacturing and R&D sectors, with many years of experience in vaccine R&D, production, quality control, and management. The company has received support under one national talent program and multiple projects under Taizhou City's "113 Talent" High-Level Innovation and Entrepreneurship Talent Program. Zhonghui Biotechnology adheres to the principle of developing innovative vaccines by avoiding mere replication and aligning with global trends. Our mission is to care for life and safeguard health. Upholding the values of innovation, pragmatism, self-discipline, integrity, and unwavering dedication, we will tirelessly strive to ensure that China gains access to cutting-edge vaccines from around the world and that the world benefits from high-quality Chinese vaccines!